trial

Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia

NCTId NCT04461119
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 138 (actual)
Sponsored by Newron Pharmaceuticals SPA
Primary completion 2021-02-20
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
138 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2020-06-16
Primary completion
2021-02-20
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Evenamide

Sponsors

Newron Pharmaceuticals SPALead Sponsor

Investigators

1
Ravi Anand, MDStudy Director

Sites

14 total
Glendale, United StatesGaithersburg, United StatesAustin, United StatesVijayawada, IndiaKoramangala, IndiaMangalore, IndiaKozhikode, IndiaPune, IndiaPune, IndiaChandigarh, IndiaLudhiana, IndiaChennai, India

Linked catalysts

1
Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patien — primary completion2021-02-20

Facts & assertions

4 sourced
Enrollment
138
Phase
PHASE2
Primary Completion Date
2021-02-20
Status
COMPLETED
relationships
The graph out of here
drug
Evenamide
drug
lead_sponsor
Newron Pharmaceuticals SPA
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ravi Anand, MD
person